S-Adenosyl Methionine Improves Early Viral Responses and Interferon-Stimulated Gene Induction in Hepatitis C Nonresponders

[Guest guest]

http://www.mdlinx.com/gastroenterology/newsl-article.cfm/3525060/ZZ6806553679256\

39220014/?news_id=511 & newsdt=040511 & subspec_id=144

S-Adenosyl Methionine Improves Early Viral Responses and Interferon-Stimulated

Gene Induction in Hepatitis C Nonresponders

Gastroenterology, 04/05/2011 Clinical Article

Feld JJ et al. - The addition of S-adenosyl methionine(SAMe) to peginterferon

and ribavirin improves the early viral kinetics and increases

interferon-stimulated gene induction in nonresponders to previous therapy. SAMe

might be a useful adjunct to peginterferon-based therapies in chronic hepatitis

C virus(HCV) infection.

Methods• Nonresponders with HCV genotype 1 were given peginterferon alfa-2a and

ribavirin for 2 weeks (course A, baseline/control).

• After 1 month, patients received SAMe (1600 mg daily) for 2 weeks and then

peginterferon and ribavirin for 48 weeks (course B; completed by 21 of 24

patients).

• Viral kinetics and interferon-stimulated gene (ISG) expression in peripheral

blood mononuclear cells (PBMCs) were compared between courses.

Results• Decrease in HCV RNA from 0 to 48 hours (phase 1) was similar with and

without SAMe.

• the second phase slope of viral decline was improved with SAMe (course A, 0.11

± 0.04 log10 IU/mL/wk; course B, 0.27 ± 0.06; P = .009).

• 11 patients (53%) achieved an early virological response, and 10 (48%) had

undetectable HCV RNA by week 24.

• Induction of ISGs in PBMCs was significantly greater during course B.

• In cultured cells, SAMe increased induction of ISGs and the antiviral effects

of interferon by increasing STAT1 methylation, possibly affecting STAT1-DNA

binding.

[Guest guest]

http://www.mdlinx.com/gastroenterology/newsl-article.cfm/3525060/ZZ6806553679256\

39220014/?news_id=511 & newsdt=040511 & subspec_id=144

S-Adenosyl Methionine Improves Early Viral Responses and Interferon-Stimulated

Gene Induction in Hepatitis C Nonresponders

Gastroenterology, 04/05/2011 Clinical Article

Feld JJ et al. - The addition of S-adenosyl methionine(SAMe) to peginterferon

and ribavirin improves the early viral kinetics and increases

interferon-stimulated gene induction in nonresponders to previous therapy. SAMe

might be a useful adjunct to peginterferon-based therapies in chronic hepatitis

C virus(HCV) infection.

Methods• Nonresponders with HCV genotype 1 were given peginterferon alfa-2a and

ribavirin for 2 weeks (course A, baseline/control).

• After 1 month, patients received SAMe (1600 mg daily) for 2 weeks and then

peginterferon and ribavirin for 48 weeks (course B; completed by 21 of 24

patients).

• Viral kinetics and interferon-stimulated gene (ISG) expression in peripheral

blood mononuclear cells (PBMCs) were compared between courses.

Results• Decrease in HCV RNA from 0 to 48 hours (phase 1) was similar with and

without SAMe.

• the second phase slope of viral decline was improved with SAMe (course A, 0.11

± 0.04 log10 IU/mL/wk; course B, 0.27 ± 0.06; P = .009).

• 11 patients (53%) achieved an early virological response, and 10 (48%) had

undetectable HCV RNA by week 24.

• Induction of ISGs in PBMCs was significantly greater during course B.

• In cultured cells, SAMe increased induction of ISGs and the antiviral effects

of interferon by increasing STAT1 methylation, possibly affecting STAT1-DNA

binding.